Overall tolerabilityNo significant difference
The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distensionNo significant differenceRR=0.49, 95% CI: 0.33-0.72
abdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal painNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication constipationNo significant differenceRR=0.38, 95% CI: 0.26-0.57
constipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant differenceRR=0.36, 95% CI: 0.26-0.48
reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication nauseaNo significant differenceRR=0.50, 95% CI: 0.37-0.68
nausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disordersNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication vomitingNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distentionReported4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002
abdominal distention (4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for constipationReported2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03
constipation (2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for diarrheaReported7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001
diarrhea (7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for overall adverse eventsReported22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001
The combination of S. boulardii and BQT had a significantly lower rate of overall adverse events (22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for